These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 36482326)

  • 21. Effect of Higher-Dose Ivermectin for 6 Days vs Placebo on Time to Sustained Recovery in Outpatients With COVID-19: A Randomized Clinical Trial.
    Naggie S; Boulware DR; Lindsell CJ; Stewart TG; Slandzicki AJ; Lim SC; Cohen J; Kavtaradze D; Amon AP; Gabriel A; Gentile N; Felker GM; Jayaweera D; McCarthy MW; Sulkowski M; Rothman RL; Wilson S; DeLong A; Remaly A; Wilder R; Collins S; Dunsmore SE; Adam SJ; Thicklin F; Hanna GJ; Ginde AA; Castro M; McTigue K; Shenkman E; Hernandez AF;
    JAMA; 2023 Mar; 329(11):888-897. PubMed ID: 36807465
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.
    Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M
    Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of hydroxychloroquine for post-exposure prophylaxis to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among adults exposed to coronavirus disease (COVID-19): a structured summary of a study protocol for a randomised controlled trial.
    Barnabas RV; Brown E; Bershteyn A; Miller RS; Wener M; Celum C; Wald A; Chu H; Wesche D; Baeten JM;
    Trials; 2020 Jun; 21(1):475. PubMed ID: 32493478
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19) a randomized, double-blind, placebo-controlled trial.
    Vallejos J; Zoni R; Bangher M; Villamandos S; Bobadilla A; Plano F; Campias C; Chaparro Campias E; Medina MF; Achinelli F; Guglielmone HA; Ojeda J; Farizano Salazar D; Andino G; Kawerin P; Dellamea S; Aquino AC; Flores V; Martemucci CN; Martinez SM; Segovia JE; Reynoso PI; Sosa NC; Robledo ME; Guarrochena JM; Vernengo MM; Ruiz Diaz N; Meza E; Aguirre MG
    BMC Infect Dis; 2021 Jul; 21(1):635. PubMed ID: 34215210
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial.
    Chaccour C; Casellas A; Blanco-Di Matteo A; Pineda I; Fernandez-Montero A; Ruiz-Castillo P; Richardson MA; Rodríguez-Mateos M; Jordán-Iborra C; Brew J; Carmona-Torre F; Giráldez M; Laso E; Gabaldón-Figueira JC; Dobaño C; Moncunill G; Yuste JR; Del Pozo JL; Rabinovich NR; Schöning V; Hammann F; Reina G; Sadaba B; Fernández-Alonso M
    EClinicalMedicine; 2021 Feb; 32():100720. PubMed ID: 33495752
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of Early Treatment with Ivermectin among Patients with Covid-19.
    Reis G; Silva EASM; Silva DCM; Thabane L; Milagres AC; Ferreira TS; Dos Santos CVQ; Campos VHS; Nogueira AMR; de Almeida APFG; Callegari ED; Neto ADF; Savassi LCM; Simplicio MIC; Ribeiro LB; Oliveira R; Harari O; Forrest JI; Ruton H; Sprague S; McKay P; Guo CM; Rowland-Yeo K; Guyatt GH; Boulware DR; Rayner CR; Mills EJ;
    N Engl J Med; 2022 May; 386(18):1721-1731. PubMed ID: 35353979
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac - PROFISCOV: A structured summary of a study protocol for a randomised controlled trial.
    Palacios R; Patiño EG; de Oliveira Piorelli R; Conde MTRP; Batista AP; Zeng G; Xin Q; Kallas EG; Flores J; Ockenhouse CF; Gast C
    Trials; 2020 Oct; 21(1):853. PubMed ID: 33059771
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High-dose ivermectin for early treatment of COVID-19 (COVER study): a randomised, double-blind, multicentre, phase II, dose-finding, proof-of-concept clinical trial.
    Buonfrate D; Chesini F; Martini D; Roncaglioni MC; Ojeda Fernandez ML; Alvisi MF; De Simone I; Rulli E; Nobili A; Casalini G; Antinori S; Gobbi M; Campoli C; Deiana M; Pomari E; Lunardi G; Tessari R; Bisoffi Z
    Int J Antimicrob Agents; 2022 Feb; 59(2):106516. PubMed ID: 34999239
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of ivermectin in patients with mild COVID-19 in Japan and Thailand.
    Mikamo H; Takahashi S; Yamagishi Y; Hirakawa A; Harada T; Nagashima H; Noguchi C; Masuko K; Maekawa H; Kashii T; Ohbayashi H; Hosokawa S; Maejima K; Yamato M; Manosuthi W; Paiboonpol S; Suganami H; Tanigawa R; Kawamura H;
    J Infect Chemother; 2024 Jun; 30(6):536-543. PubMed ID: 38154616
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of Ivermectin as a Potential Treatment for Mild to Moderate COVID-19: A Double-Blind Randomized Placebo Controlled Trial in Eastern India.
    Ravikirti ; Roy R; Pattadar C; Raj R; Agarwal N; Biswas B; Manjhi PK; Rai DK; Shyama ; Kumar A; Sarfaraz A
    J Pharm Pharm Sci; 2021; 24():343-350. PubMed ID: 34265236
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Controlled, double-blind, randomized trial to assess the efficacy and safety of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in healthcare personnel in the hospital setting: A structured summary of a study protocol for a randomised controlled trial.
    Cuadrado-Lavín A; Olmos JM; Cifrian JM; Gimenez T; Gandarillas MA; García-Saiz M; Rebollo MH; Martínez-Taboada V; López-Hoyos M; Fariñas MC; Crespo J
    Trials; 2020 Jun; 21(1):472. PubMed ID: 32493494
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti-COVID property of subcutaneous ivermectin in synergy with zinc among midlife moderately symptomatic patients: a structured summary of a study protocol for a randomised controlled trial.
    Ashraf S; Ashraf S; Farooq I; Ashraf S; Ashraf M; Imran MA; Kalsoom L; Akmal R; Ghufran M; Rafique S; Akram MK; Habib Z; Siddiqui UN; Ahmad A; Arshad S; Virk MAR; Gul M; Awais AB; Hassan M; Sherazi SSH; Safdar Z; Munir I; Khalid H; Munir K; Majeed N; Alahmadi YM; Humayun A; Saboor QA; Ahmad A; Ashraf M; Izhar M;
    Trials; 2021 Sep; 22(1):591. PubMed ID: 34488858
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19: A Randomized Clinical Trial.
    López-Medina E; López P; Hurtado IC; Dávalos DM; Ramirez O; Martínez E; Díazgranados JA; Oñate JM; Chavarriaga H; Herrera S; Parra B; Libreros G; Jaramillo R; Avendaño AC; Toro DF; Torres M; Lesmes MC; Rios CA; Caicedo I
    JAMA; 2021 Apr; 325(14):1426-1435. PubMed ID: 33662102
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19.
    Bramante CT; Huling JD; Tignanelli CJ; Buse JB; Liebovitz DM; Nicklas JM; Cohen K; Puskarich MA; Belani HK; Proper JL; Siegel LK; Klatt NR; Odde DJ; Luke DG; Anderson B; Karger AB; Ingraham NE; Hartman KM; Rao V; Hagen AA; Patel B; Fenno SL; Avula N; Reddy NV; Erickson SM; Lindberg S; Fricton R; Lee S; Zaman A; Saveraid HG; Tordsen WJ; Pullen MF; Biros M; Sherwood NE; Thompson JL; Boulware DR; Murray TA;
    N Engl J Med; 2022 Aug; 387(7):599-610. PubMed ID: 36070710
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A randomized, double-blind study on the efficacy of oral domperidone versus placebo for reducing SARS-CoV-2 viral load in mild-to-moderate COVID-19 patients in primary health care.
    Rabanal Basalo A; Navarro Pablos M; Viejo Pinero N; Vila Méndez ML; Molina Barcena V; Montilla Bernabé A; Villanueva Morán MDP; Blanco Gallego AM; Guirao Sánchez C; Juárez Antón S; Fernández Rodríguez Á; Revuelta Puigdollers ML; Sarriá Sánchez MT; Martín Alegre C; Martínez Álvarez MÁ; Mestre de Juan M; Mielgo Salvador R; Gijón Seco MT; Saníger Herrera JM; Rodríguez Jiménez ME; Navas de la Peña B; Santa Cruz Hernández J; Abad Esteban AM; Díaz Martín R; García Pérez L; Herrero Vanrell P; Arias de Saavedra Criado MI; Vaquero Vinent A; López Gómez V; Montegrifo Rentero VM; Simón Miguel L; Campo Martos I; Ortiz Zamorano S; Izquierdo Zamarriego MJ; Vázquez Carrión I; López Valero RM; Gil C; Martínez A; Soler López B
    Ann Med; 2023; 55(2):2268535. PubMed ID: 37847999
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial.
    Feld JJ; Kandel C; Biondi MJ; Kozak RA; Zahoor MA; Lemieux C; Borgia SM; Boggild AK; Powis J; McCready J; Tan DHS; Chan T; Coburn B; Kumar D; Humar A; Chan A; O'Neil B; Noureldin S; Booth J; Hong R; Smookler D; Aleyadeh W; Patel A; Barber B; Casey J; Hiebert R; Mistry H; Choong I; Hislop C; Santer DM; Lorne Tyrrell D; Glenn JS; Gehring AJ; Janssen HLA; Hansen BE
    Lancet Respir Med; 2021 May; 9(5):498-510. PubMed ID: 33556319
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials.
    Yang S; Li Y; Dai L; Wang J; He P; Li C; Fang X; Wang C; Zhao X; Huang E; Wu C; Zhong Z; Wang F; Duan X; Tian S; Wu L; Liu Y; Luo Y; Chen Z; Li F; Li J; Yu X; Ren H; Liu L; Meng S; Yan J; Hu Z; Gao L; Gao GF
    Lancet Infect Dis; 2021 Aug; 21(8):1107-1119. PubMed ID: 33773111
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of a Single Dose of Ivermectin on Viral and Clinical Outcomes in Asymptomatic SARS-CoV-2 Infected Subjects: A Pilot Clinical Trial in Lebanon.
    Samaha AA; Mouawia H; Fawaz M; Hassan H; Salami A; Bazzal AA; Saab HB; Al-Wakeel M; Alsaabi A; Chouman M; Moussawi MA; Ayoub H; Raad A; Hajjeh O; Eid AH; Raad H
    Viruses; 2021 May; 13(6):. PubMed ID: 34073401
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Multicenter Randomized Controlled Trial To Evaluate the Efficacy and Safety of Nelfinavir in Patients with Mild COVID-19.
    Miyazaki T; Hosogaya N; Fukushige Y; Takemori S; Morimoto S; Yamamoto H; Hori M; Ozawa Y; Shiko Y; Inaba Y; Kurokawa T; Hanaoka H; Iwanami S; Kim K; Iwami S; Watashi K; Miyazawa K; Umeyama T; Yamagoe S; Miyazaki Y; Wakita T; Sumiyoshi M; Hirayama T; Izumikawa K; Yanagihara K; Mukae H; Kawasuji H; Yamamoto Y; Tarumoto N; Ishii H; Ohno H; Yatera K; Kakeya H; Kichikawa Y; Kato Y; Matsumoto T; Saito M; Yotsuyanagi H; Kohno S
    Microbiol Spectr; 2023 Jun; 11(3):e0431122. PubMed ID: 37140398
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A randomized trial to assess the acceleration of viral clearance by the combination Favipiravir/Ivermectin/Niclosamide in mild-to-moderate COVID-19 adult patients (FINCOV).
    Siripongboonsitti T; Tawinprai K; Avirutnan P; Jitobaom K; Auewarakul P
    J Infect Public Health; 2024 May; 17(5):897-905. PubMed ID: 38569269
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.